Tag Archives: Affordable Care Act

Are US and Canadian Rx Policies Converging?

by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program.  To say that this is a critical concern for the […]
Posted in Global, Guest Blog, healthcare, Legal, Market Access, Strategy | Also tagged , , , , , | Leave a comment

Questions About the 2013 Implementation of IPAB

by Tom Norton With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun.  Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th.   A huge amount of activity, to be sure, but as stated, not surprising.  That’s because the […]
Posted in FDA, healthcare, Legal, Market Access, pricing, Regulatory | Also tagged , , , , , , | Leave a comment

Pharma Gains from Rule On Health Insurance Benefits

Recent change likely to boost drug coverage by plans, but with variation in formularies. Health plans offering coverage to individuals and small companies are more likely to cover multiple drugs in each class or category under revised regulations proposed by the Department of Health and Human Services in November. A key change in rules to […]
Posted in healthcare, Legal, Regulatory, Strategy | Also tagged , , , | Leave a comment

With the Election Decided, It's Full Speed Ahead on ObamaCare

by Tom Norton With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare.  Here are some of the key actions to anticipate between now and January 1, 2013.
Posted in FDA, healthcare, Legal, Regulatory, Strategy | Also tagged , , , , , | 3 Comments

What the Affordable Care Act Means for Pharma Marketing

By Gregg DiPietro. With the Supreme Court’s decision in June to uphold the Patient Protection and Affordable Care Act (ACA), life science companies gained access to 32 million potential new customers. While that’s worth celebrating, the party may have ended before it began. For pharmaceutical companies to realize the benefits of new healthcare consumers, and […]
Posted in Guest Blog, Regulatory, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta